Healthcare Weekly Report: Henlius Submits Hong Kong IPO Application; Dain Pharmaceutical and Jointown Pharma Announce Strategic Partnership

Henan Zhenzhen Biotechnology Co., Ltd.'s Hong Kong IPO Application Accepted

On February 18, the Hong Kong IPO application of Henan Zhenzhen Biotechnology Co., Ltd. was accepted, and the prospectus was officially disclosed. It is reported that Zhenzhen Biotechnology first submitted its listing application to the Hong Kong Stock Exchange in August 2022 but failed to pass the hearing within six months, causing the application to lapse. This is Zhenzhen Biotechnology's second attempt to go public on the Hong Kong Stock Exchange. As the halo of COVID-19 miracle drugs fades, will the capital market be willing to invest in an innovative pharmaceutical company that has yet to turn a profit? Can a single new drug justify an entire IPO? (Source: Arterial Network)

Shandong Dayin Marine Biological Pharmaceutical Co., Ltd. and GUANGZHOU JOINTOWN PHARMACEUTICAL CO.,LTD Reach Strategic Cooperation

On February 20, 2025, Jointown Pharmaceutical Group and Shandong Dayin Marine Biological Pharmaceutical Co., Ltd. officially signed the 2025 Strategic Cooperation Agreement in Beijing. According to the agreement, the two parties will integrate Jointown's efficient distribution network covering all of China and Dayin Pharmaceutical’s R&D advantages in pediatric medicines and health products. The collaboration will deepen around Dayin Pharmaceutical’s product lines, focusing on strategic cooperation in areas such as in-depth distribution, e-commerce delivery, core chain delivery, broad market coverage, hospital delivery, and key project coordination, jointly promoting high-quality development in the pharmaceuticals and healthcare industry. (Source: Securities Times)

For the First Time Globally, Fudan University Research Team Discovers New Therapeutic Target for Parkinson's Disease

Fudan University Huashan Hospital's Yu Jintai Team Discovers New Therapeutic Target FAM171A2 for Parkinson’s Disease after 5-Year Study, Revealing Its Binding Mechanism with Key Pathogenic Protein α-Synuclein. The study found that FAM171A2 transports pathological α-synuclein into neurons, causing neuronal death and the spread of pathogenic proteins. Through transgenic animal experiments, the team confirmed that knocking out FAM171A2 effectively controls the progression of Parkinson-like symptoms. (Source: Jiemian News)

Pharmaron Completes Controlling Stake Transaction in Zhejiang Haihui Technology Co., Ltd.

On February 20, 2025, Pharmaron, a CXO company listed on the A-share market, announced that its subsidiary, Pharmaron Clinical Research Services Co., Ltd., had completed the controlling transaction of Zhejiang Haihui Technology Co., Ltd. on February 19. This transaction marks that Pharmaron Clinical will integrate Haihui Technology's high-quality compliant patient data and AI technology platform to expand the provision of premium personalized patient management services and promote the digital and intelligent upgrading of the company’s innovative drug R&D service capabilities and systems. (Source: Arterial Network)

TI Global Leader Neurodome Completes Series A Financing

Recently, Neurodome, Inc. (hereinafter referred to as "Neurodome"), an innovator and leader in non-invasive deep brain neuromodulation technology, successfully completed a multi-million yuan Series A round of financing. This round was co-led by Huafang Capital and iFlytek Ventures, with participation from Heging Capital. Xingyuan Zhicheng served as the exclusive financial advisor for this round. The proceeds will help accelerate the company's ongoing exploration and development of Temporal Interference (TI) technology in the field of brain science, promote multi-scenario product solutions, and advance clinical registration, product certification, and commercialization for various indications. (Source: Vbdata.cn)

Reedlin Completes Over 500 Million Yuan in Series C Financing

Recently, Shenzhen Reedlin Biotechnology Co., Ltd. (hereinafter referred to as "Reedlin") announced the completion of a C-round financing exceeding 500 million yuan, jointly invested by Songhe Capital, Cornerstone Capital, Changde Xingxin, Baiyin Kejian, and Changde Deyuan. The investors' background includes the management entities of government or industrial funds such as Shenzhen's "20+8" Future Industry Fund, the sub-fund of the National Science and Technology Achievement Transformation Guidance Fund, and the Changde Synthetic Biology Fund. (Source: Arterial Network)

Hengyu Medical Completes Over 100 Million Yuan in Financing

Recently, Tianjin Hengyu Medical Technology Co., Ltd. ("Hengyu Medical" for short) announced the completion of a financing round exceeding 100 million yuan. This round was jointly invested by Xingong Industrial Investment, Huatai Zijin, Beiyang Haitang Fund, Jiuan Medical (002432.SZ), and YuanSheng Ventures. StarBridge Capital served as the exclusive financial advisor. This round of financing will support R&D, production, and registration, with a particular focus on accelerating the commercialization process of already listed products. (Source: Arterial Network)

Mashizera, a Leading Enterprise in Medical Nutrition, Completes a New Round of Financing Worth Nearly 200 Million Yuan

Recently, Mashi-Sarai (Shanghai) Biotechnology Co., Ltd. (hereinafter referred to as "Mashi-Sarai") announced the completion of a nearly 200 million yuan Series B financing round. This round was jointly led by funds under CICC Capital, Hongsheng Capital, and Honghui Fund, with participation from Fengqiao Capital and Frees Fund. Winland Capital served as the exclusive financial advisor. The financing round received high recognition and strong support from well-known investment institutions and existing shareholders. The proceeds will mainly be used to accelerate the development of a series of medical nutrition products, further expand the company's scale and leading position in the three business segments of specialized medical nutrition, energy control, and DGI blood sugar control, and expedite the fulfillment of the corporate mission to make medical nutrition universally accessible. (Source: Arterial Network)

North China Pharmaceutical Expects Approximately 125 Million in Net Profit Attributable to Shareholders for 2024

Recently, North China Pharmaceutical's Finerenone Tablets have been accepted for production declaration as a Category 4 generic drug, striving to become the first domestically produced generic in China. As a large state-owned pharmaceutical enterprise in China, North China Pharmaceutical is projected to achieve a net profit attributable to shareholders of approximately 125 million yuan in 2024, marking an increase of about 2456% year-on-year, with its first innovative drug (Category 1) achieving rapid market expansion. Currently, the company has 41 varieties that have passed or are considered to have passed quality and efficacy evaluations, while three major products are preparing for inclusion in the 11th round of national procurement. In terms of R&D pipeline, seven new drugs are at the clinical approval stage or higher, and 12 varieties are under review for production registration under the new classification system. (Source: Menet)

Anhui Clarifies: Full Coverage of Traceability Codes by July, "No Code, No Payment"

On February 19, the Anhui Provincial Medical Security Bureau released the "Key Work Task List for 2025 of the Provincial Medical Insurance Bureau," clarifying the main direction and specific tasks for the year’s medical insurance work. There are a total of 20 key tasks, including carrying out no less than one batch of provincial inter-provincial drug and consumables centralized procurement, and leading the national biopharmaceuticals alliance procurement. Additionally, there will be significant empowerment of medical institutions, pharmaceutical enterprises, and commercial insurance, with considerable policy support. Efforts will also be made to advance pharmaceutical price governance, promoting consensus on the listing price rules for drugs; further exploration of designated retail pharmacy drug price management will continue, advancing price disclosure, monitoring, and governance at designated retail pharmacies, and developing a province-wide unified drug price comparison system. The implementation of traceability codes will be accelerated, with full coverage required by the end of July, and clear requirements that payments will not be made without codes. (Source: Menet)